Ranexa ahead of schedule
This article was originally published in Pharmaceutical Approvals Monthly
CV Therapeutics expects to complete enrollment of its "approval-enabling study" of Ranexa by the end of the first quarter of 2005, the firm says Oct. 26. Prior to initiation in August 2004, the firm expected to complete enrollment of the Evaluation of Ranolazine In Chronic Angina study by the end of 2005. ERICA is being conducted under a special protocol assessment with FDA and is comparing ranolazine to the calcium channel blocker amlodipine (Pfizer's Norvasc) in 500 refractory chronic angina patients. Ranexa has been "approvable" at FDA since Oct. 30, 2003. Another study, MERLIN, is ongoing in support of a first-line indication (1Pharmaceutical Approvals Monthly Aug. 1, 2004, p. 10)...
You may also be interested in...
CV Therapeutics’ Ranexa could receive the first approval for first-line treatment of chronic angina if a new outcomes trial does not detect a trend towards death or arrhythmia, the company said.
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.